Ovarian cancer data give Corcept’s shares a bounce after year-end CRL drop 

On Thursday, positive Phase III data for Corcept’s relacorilant in ovarian cancer helped the biotech’s shares claw back some gains after a complete response letter ended a multi-quarter run in the stock on the final day of 2025. 

Relacorilant, a small molecule GPCR antagonist for hypercortisolism and platinum-resistant ovarian cancer from Redwood City, Calif.-based Corcept Therapeutics Inc. (NASDAQ:CORT), drove the biotech’s stock in 2024-25 to new heights, including an all-time high of $117.33 on March 31, 2025. The year-end CRL for relacorilant in hypercortisolism on 2025’s final day slashed the company’s shares by 50%. The setback left the company as the worst-performing large-cap stock in 4Q25, down 58% to $3.7 billion in market cap...